Navigation Links
Depomed Reports Third Quarter Financial Results
Date:11/5/2012

MENLO PARK, Calif., Nov. 5, 2012 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today reported financial results for the quarter and nine months ended September 30, 2012.

2012 Third Quarter and Recent Business Highlights

  • Financial Highlights:
  • Revenue of $33.3 million for the third quarter and $64.2 million for the nine months ended September 30
  • Net loss of ($1.5) million or ($0.03) per share for the third quarter and ($26.1) million or ($0.47) per share for the nine months ended September 30
  • $87.7 million of cash and marketable securities and no debt
  • Gralise® (gabapentin) Highlights:
  • Gralise product sales of $4.8 million for the third quarter
  • Gralise prescription demand now over 3,500 per week
  • Approximately 8,500 physicians have prescribed Gralise since launch
  • Zipsor® (diclofenac potassium) Highlights:
  • Zipsor product sales of $4.9 million for the third quarter
  • Depomed promotion commenced at the end of July 2012
  • Glumetza® (metformin hydrochloride extended release tablets) Highlights:
  • Royalty of $11.6 million on third quarter Glumetza sales
  • Technology and R&D Highlights:
  • License agreement with Janssen Pharmaceuticals for Nucynta ER; $10 million upfront payment received in September; royalties started July 2, 2012 and continue through 2021
  • Serada NDA accepted by FDA; Advisory Committee meeting tentatively scheduled for March 4, 2013; PDUFA date of May 31, 2013
  • "During the third quarter, Gralise prescriptions continued to grow, we relaunched Zipsor, Glumetza royalties for the quarter exceeded $11 million, we expanded our portfolio of license and development agreements with our license to Janssen for Nucynta ER and received a $10 million upfront payment. In October, the F
    '/>"/>

    SOURCE Depomed, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Depomed To Report Third Quarter Fiscal Year 2012 Financial Results On Monday, November 5, 2012
    2. Depomed To Present At UBS Global Life Sciences Conference
    3. Depomed To Present At Morgan Stanley 2012 Healthcare Conference
    4. Depomed To Present At Stifel Nicolaus 2012 Healthcare Conference
    5. Depomed To Report Second Quarter Fiscal Year 2012 Financial Results On Thursday, August 2, 2012
    6. Depomed To Present At JMP Securities 7th Annual Healthcare Conference
    7. Depomed Announces Filing Of Shelf Registration To Replace Existing Shelf
    8. Depomed To Present At Jefferies 2012 Global Health Care Conference
    9. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
    10. Cambrex Reports Third Quarter 2012 Financial Results
    11. Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/2/2014)... 2014   Intarcia Therapeutics, Inc. today announced ... 3 clinical trials for ITCA 650 (exenatide, delivered continuously ... mini-pump). The first trial, FREEDOM-1, was a placebo-controlled, double-blind ... safety of ITCA 650 in patients with type 2 ... be significantly superior to placebo for both 40 mcg ...
    (Date:10/1/2014)... , Oct. 1, 2014 The ... available. Interested parties can learn about the ... Health is supporting the health care continuum ... . Photo- http://photos.prnewswire.com/prnh/20140930/149504-INFO ... financials and the chief executive officer,s letter ...
    (Date:10/1/2014)... , Oct. 1, 2014  Dyadic International, ... with patented and proprietary technology used to develop ... bioenergy, bio-based chemicals, biopharmaceuticals, and industrial enzymes industries, ... payment from Abengoa Bioenergy for commercial scale production ... biomass into ethanol, developed under Abengoa,s license agreement ...
    Breaking Medicine Technology:Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Cardinal Health 2014 Digital Report to Shareholders Now Available 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3
    ... May 3, 2012   Kensey Nash Corporation (Nasdaq: KNSY ... with Royal DSM (DSM) (NYSE Euronext: DSM KON), under which DSM ... Nash through a cash tender offer, followed by a merger with ... "We are very pleased to have entered into the ...
    ... CAESAREA, Israel, May 2, 2012 Angioslide ... announced that it has received FDA 510(K) clearance for ... Disease in below the knee (BTK) vasculature.  The new ... potential use of PROTEUS technology.   Angioslide,s ...
    Cached Medicine Technology:Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 2Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 3Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 4Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 5Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 6Angioslide Announces FDA 510(K) Clearance of PROTEUS(TM) Below The Knee Device 2
    (Date:10/1/2014)... BOSTON (October 1, 2014) Despite a policy ... with developmental disabilities, this vulnerable population continues to ... of The Journal of the American Dental ... Medicine and Tufts University School of Dental Medicine ... factors influencing at-home oral care provided by caregivers ...
    (Date:10/1/2014)... October 01, 2014 Familylifeinsurancequotes.org has ... life insurance for senior citizens. , Senior citizens ... will now sell coverage to seniors who are over ... be purchased without taking a medical examination. , Term ... online and senior clients can qualify. Having life insurance ...
    (Date:10/1/2014)... Insuranceragents.info has released a new blog post ... for vulnerable family members. , Life insurance plans provide ... the family should always carry a life insurance policy ... rest of the family. , Clients can choose ... from temporary coverage or from a permanent policy. No ...
    (Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog post explaining ... smokers. , Smoking will always have a negative impact ... best method to find affordable coverage. Insurance brokerage websites ... , Whole life insurance premiums will be fixed ... coverage is permanent, the initial rates are very ...
    (Date:10/1/2014)... Phoseon Technology, the pioneer in developing ... business worldwide. This rapid growth includes increased hiring for ... efforts. The company has experienced average annual growth rates ... this growth to continue in the future as new ... , “We are very pleased that UV ...
    Breaking Medicine News(10 mins):Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2
    ... 28 Following the feature of the UltraPulse CO2 fractional laser ... Show , The Insider will also be featuring the ... and Trae Berns were interviewed today by The Insider . ... they have lived with for 20 years. The girls also discussed ...
    ... 28 Nuvilex, Inc. (OTC Bulletin Board: NVLX), an ... Kentrist 41 Direct, Inc. (CK41), the Company,s joint venture ... has updated its product launch plans. The previously announced ... Mr. Savage, CK41,s new Chief Executive Officer, to impart ...
    ... 28 Air Products, (NYSE: APD ... at www.airproducts.com/Responsibility/2009CRAR/index.asp . "In these trying times ... improved sustainability performance for our customers and our ... Products, chairman, president and chief executive officer. ...
    ... the American Heart Association, "silent" or "hidden" heart attacks ... are left untreated.Saint Francis Hospital in Evanston, Ill. has ... offer a new test for chest pain patients that ... The uniqueness of the new test lies in a ...
    ... Monday, June 1, 20091:30 to 2:30 p.m. Rooftop garden offers patients quiet haven, conservatory features ... Aurora St. Luke,s Medical Center is dedicating the Vince, ... Funds Healing Garden and the Agnes and, ... Monday, June 1, 1:30 to 2:30 p.m., WHERE: ...
    ... in Health Affairs finds that a Massachusetts ... has resulted in higher costs. This predictable result confirms ... must be a part of national health reform, said ... that reform is unaffordable without a public option like ...
    Cached Medicine News:Health News:Miracle Treatment for Burn Scars as Seen on Today Show Will Also Be Featured on The Insider Tonight 2Health News:Miracle Treatment for Burn Scars as Seen on Today Show Will Also Be Featured on The Insider Tonight 3Health News:Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan 2Health News:Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan 3Health News:Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan 4Health News:Air Products' 2009 Corporate Responsibility Report Now Available 2Health News:Finding Hidden Heart Attacks: Saint Francis Hospital is First in Illinois to Detect Hidden Heart Attacks With New Technology 2Health News:Health Affairs Report On Mass. Mandatory Insurance Law Confirms: Strong Public Option Must Be Included in National Health Reform 2Health News:Health Affairs Report On Mass. Mandatory Insurance Law Confirms: Strong Public Option Must Be Included in National Health Reform 3
    ... VISUCAM non-mydriatic fundus camera ... simplicity of fundus imaging. ... to set the standard ... features a unique combination ...
    ... Afinion HbA1c test and the ... you reliable facts conveniently available ... them. Advising the patient can ... The HbA1c Test Cartridge contains ...
    An aid for advancing a pacemaker lead through the subcutaneous tissue of the chest wall to the pacemaker pocket....
    The ARK-730A initiates automatic measurement at the optimum measurement point. The ARK-730A maintains fogging throughout multiple measurements, saving total examination time....
    Medicine Products: